Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS: During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with placebo, OM reduced incidence of the primary outcome over 22 months of follow-up (37.0% vs 39.1%; HR, 0.92 [95% CI 0.85-0.99]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationRegularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
Simon, N., Friedman, J., Hastie, T., & Tibshirani, R. (2011) · Journal of Statistical Software · doi:10.18637/jss.v039.i05 · Cited by 2,499
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationCardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationRepeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
Kramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Cited by
Items 501–600 of 709
Új lehetőség a szisztolés szívelégtelenség (HFrEF) kezelésében: omecamtiv-mecarbil
Ráduly, A. P., Tóth, A., Papp, Z., & Borbély, A. (2021) · Cardiologia Hungarica · doi:10.26430/chungarica.2021.51.2.118 · Cited by 1
Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure
Mack, M., & Frishman, W. H. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000530 · Cited by 1
Manejo multidisciplinario y terapia paliativa en falla cardiaca avanzada, revisión de la evidencia
Dulcey, L., Therán, J. S., Cabrera, V., Parales, R., Caltagironne, R., Blanco, E., & Ciliberti, M. (2023) · Acta Bioclínica · doi:10.53766/acbio/2023.14.27.07 · Cited by 1
Lund, L. H., Aizpurua, A. B., Bollano, E., Braun, O. B., Brouwer, J. L. P., Buikema, J. W., Cannata, A. N., Gardner, R. S., Handoko, M. L., Lang, C. C., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00904-9 · Cited by 1
Self-citationLow-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure
Chimura, M., Pellicori, P., Docherty, K. F., Claggett, B. L., Campbell, R. T., Desai, A. S., Packer, M., Jhund, P. S., Petrie, M. C., Rouleau, J. L., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.013 · Cited by 1
Self-citationMolecular and cellular biology and genetic factors in chronic heart failure
Singh, R. B., Singh, J., Bidasee, K. R., Isaza, A., Rupee, S., Rupee, K., Hanoman, C., Adeghate, E. A., & Smail, M. M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822972-9.00016-x · Cited by 1
Recent Advancements in the Management of Heart Failure: A Review
Sanyaolu, S. E. (2025) · Premier Journal of Cardiology · doi:10.70389/pjc.100008 · Cited by 1
Harnessing the gut microbiome for precision therapeutics in heart failure
Li, J., Zhang, S., Zhang, Y., 王鑫磊, Zhuge, Y., Wu, Q., Zhao, Y., Gao, Q., Chen, R., Wang, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1781470 · Cited by 1
Self-citationChimura, M., Docherty, K. F., Jhund, P. S., Yang, M., Ono, R., Henderson, A. D., Cleland, J. G. F., Metra, M., Liu, G., Divanji, P., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag007 · Cited by 1
Self-citationLu, H. Y., Claggett, B. L., Felker, G. M., McMurray, J. J. V., Teerlink, J. R., Inciardi, R. M., Metra, M., Heitner, S. B., Díaz, R., Malik, F. I., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102703 · Cited by 1
Self-citationThe role of ischaemic heart disease in heart failure
Montone, R. A., Volterrani, M., Zhang, J., & Crea, F. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0003 · Cited by 1
Sun, J., & Cook, T. (2025) · Statistics in Medicine · doi:10.1002/sim.70311 · Cited by 1
Cabré, F., & Cascante, M. (2026) · Medical Sciences · doi:10.3390/medsci14020331 · Cited by 1
Ting, C.-Y., Shih, C., Yu, M., Wu, C., & Wu, S. (2023) · Biomedicines · doi:10.3390/biomedicines11051351 · Cited by 1
Modern trends in pharmacological treatment heart failure
Vítovec, J., Špinar, J., & Špinarová, L. (2021) · Klinická farmakologie a farmacie · doi:10.36290/far.2021.009 · Cited by 1
Cruz‐Cortés, C., Šeflová, J., & Espinoza‐Fonseca, L. M. (2025) · Biomedicines · doi:10.3390/biomedicines13123036 · Cited by 1
Revisiting Beta-Blocker Formulation—What’s Old Is New Again
BEAVERS, J., & CARTER, S. (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.12.004 · Cited by 1
Phenotype-specific prognostic implications of pulse pressure in heart failure
Chimura, M., Docherty, K. F., Henderson, A. D., Desai, A. S., Komajda, M., Packer, M., Pfeffer, M. A., Pitt, B., Teerlink, J. R., Vaduganathan, M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag292 · Cited by 1
Self-citationVIII Международный образовательный форум “Российские дни сердца”. Дневник проекта
Lyapina, I. N., Чичкова, Т. Ю., & Teplova, Y. E. (2021) · Russian Journal of Cardiology · Cited by 1
Lu, H., Roux, O., Fournier, S., Aur, S., Hullin, R., Antiochos, P., Pucci, L., Monney, P., Schwitter, J., Bloa, M. L., et al. (2022) · JMIG · doi:10.53738/revmed.2022.18.767.144 · Cited by 1
Nueva guía de insuficiencia cardiaca de la HFA-ESC 2021. Un enfoque práctico e integral
Manito, N. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2022.01.009 · Cited by 1
Mi az eredményesebb stratégia: a miozin aktivációja vagy gátlása?
Papp, Z., Sárkány, F., Ráduly, A. P., Pásztor, D. Z., Máté, B. I., Tóth, A., & Borbély, A. (2023) · Cardiologia Hungarica · doi:10.26430/chungarica.2023.53.4.331 · Cited by 1
Behandling av hjärtsvikt för bättre prognos och större livskvalitet
Lassus, J. P. E. (2021) · Helda - University of Helsinki Institutional Repository · Cited by 1
Omecamtiv mecarbil for patients with severe systolic dysfunction and hypotension
Crespo-Leiro, M. G., McDonagh, T. A., & Barge‐Caballero, E. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac552 · Cited by 1
Self-citationPromoting Representation in Heart Failure Clinical Trials
Gupta, M., Fiuzat, M., Dimond, M. G., Blumer, V. L., Jessup, M. L., Ibrahim, N. E., Adamson, P. B., Vaduganathan, M., Lindenfeld, J., Yancy, C. W., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.033 · Cited by 1
The Chronic Systolic Heart Failure Patient: Presentation and Management
Bitar, A., & Aaronson, K. D. (2023) · Wiley eBooks · doi:10.1002/9781119633884.ch13
PERICARDITE AGUDA E TAMPONAMENTO CARDÍACO
Neto, P. R. M., Matos, L. E. O., Júnior, M. V. D. N., Portela, B. M. L., & Reis, B. C. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ceg164.1123-12
SÍNDROME CORONARIANA COM SUPRA DE ST (SCA CSST)
Mendes, D. M., Magalhães, I., Cabral, L. D., Mendonça, P. J. L. D. A., & Neto, J. D. C. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ceg164.1123-7
Portela, B. M. L., Freitas, J. I. D. C., Ferreira, M. A., Mendonça, P. J. L. D. A., & Neto, J. D. C. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ceg164.1123-2
Die ESC-Leitlinien zur Herzinsuffizienz im Spiegel aktueller Evidenz
Ghorani, H. A., Böhm, M., & Abdin, A. (2025) · Kardiologie up2date · doi:10.1055/a-2461-7287
Self-citationOjrzanowski, M., & Kasprzak, J. D. (2021) · Folia Cardiologica · doi:10.5603/fc.2021.0018
Gomez-Cid, L., Moro-López, M., Nava, A., Fernandez, A. I., Fernández‐Santos, M. E., Atienza, F., Grigorian, L., & Fernández‐Avilés, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab724.3317
Freixedelo, B. D. A., Carneiro, J. M. D. F., Neto, P. R. M., Portela, B. M. L., & Monteiro, D. L. S. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ceg164.1123-8
Barbosa, A. V., Silva, L. C. A., Rotta, I., & Aguiar, P. M. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.04.082
Traitement pharmacologique de l’insuffisance cardiaque
Logeart, D. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.03.002
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Simões, M. V., Moura, L. Z., Martins, S. M., Mourilhe‐Rocha, R., Danzmann, L. C., Neto, J. A. D. F., Marcondes‐Braga, F. G., de Oliveira, M. T., de Albuquerque, D. C., Freitas, A. F., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260830 · Cited by 1
Self-citationErtürk, E., Ocak, K., Uyan, U., Çoner, A., Kocabaş, U., Kış, M., Başkurt, A. A., Oray, D., Sayın, B. Y., Mammadov, G., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2688
Thompson, E. J., Li, J. S., & Hornik, C. P. V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11851-7.00026-4
Self-citationWagle, A., Bharati, B., Dimadi, I. I. Y., & Varma, N. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001430
Lo mejor del 2020: estudios que marcarán nuestra práctica clínica
Paredes-Paucar, C., & Chacón-Díaz, M. (2020) · Archivos Peruanos de Cardiología y Cirugía Cardiovascular · doi:10.47487/apcyccv.v1i4.101
Lo mejor del 2020: Estudios que marcarán nuestra práctica clínica
Paredes-Paucar, C., & Chacón-Díaz, M. (2020) · Archivos Peruanos de Cardiología y Cirugía Cardiovascular · doi:10.47487/apcyccv.v2i1.101
Neue Therapien der Herzinsuffizienz mit reduzierter Ejektionsfraktion
Langhammer, R., & Wachter, R. (2021) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-021-9806-x
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
Bueno, H., Moura, B., Lancellotti, P., & Bauersachs, J. K. (2021) · Cardiologia Croatica · doi:10.15836/ccar2021.140
Rohant, N., & Kennedy, J. L. W. (2021) · Heart International · doi:10.17925/hi.2021.15.1.42
Ono, K., Horie, T., & Baba, O. (2025) · Asian Heart Journal · doi:10.1097/ah9.0000000000000009
Emerging Targeted Therapies for Inherited Cardiomyopathies and Arrhythmias
Ryan, T. L., & Roberts, J. D. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.08.004
Clinical phenotypes of heart failure with reduced ejection fraction
Halliday, B. P., & Lüscher, T. F. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0028
Heart failure in diabetes: Current clinical management
Santiago‐Vacas, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00014-2
May, H. T., Anderson, J. L., Butzner, M., Divanji, P., & Muhlestein, J. B. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae081
Cardiac Myosin Activators in Heart Failure: Experimental Advances Amid Clinical Uncertainty
Hou, L., Lin, B., Ji, X., & Huang, A. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s568587
Targeting cardiac myosin in HFrEF: mechanism, clinical evidence, and the role of omecamtiv mecarbil
Abady, E. M. A., Elewa, M., Karam, K. N., Mathew, K., Bedair, M., Almashaqbeh, S. N., Alwarraqi, A. G., AbuEl-Enien, H., Samadi, Y., & Abouelmagd, K. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-04427-9
Guidelines for the management of chronic heart failure
Hadi, N. R., Fedačko, J., Singh, R. B., Elkilany, G. N., Elmaraghi, O., Hamdy, E. A., Hristová, K., Chakravorty, S., Shogenova, L. V., Slezák, J., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822972-9.00031-6
Regulation of vesicular trafficking in presence of mutations in contractile proteins
Dai, Y. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9210
Electrolyte disturbances in heart failure: focus on sodium and potassium
Beusekamp, J. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.196047233
Papadimitriou, L., Hernandez, G. A., Lennep, B., Long, R. C., Butler, J., & Kalogeropoulos, A. P. (2021) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-021-00905-6
Lo mejor del congreso virtual de AHA2020
Gianoni, K., de Sosa, D., Lorente, M., & Noria, S. (2021) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.36.1.6
Wu, H., Wen, Y., Huang, J., Zhang, L., & Yang, X. (2021) · Research Square · doi:10.21203/rs.3.rs-962831/v1
Acute heart failure: early pharmacological therapy
Docherty, K. F., Dalzell, J. R., Petrie, M. C., & McMurray, J. J. V. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198849346.003.0047
Self-citationAddressing the Clinical and Economic Impact of Heart Failure
(2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89416
New therapeutic strategies for heart failure
Rossano, J. W., Dreyer, W. J., & Jefferies, J. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13279-7.00056-0
Yu, X., Cui, C., He, J., Guan, X., & Zhang, Z. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1805737
Unmet Needs in Drug Treatment of Heart Failure in Hypertension
Boutouyrie, P., & Fayol, A. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_26
Maturing Engineered Heart Tissues for Titin-Based Disease Modeling
Keschrumrus, V. (2021) · UA Campus Repository (The University of Arizona)
Faber, R. A., Baart, V. M., Bordo, M. W., March, T. L., Valentijn, A. R. P. M., Harmsen, S., Pool, M., Burggraaf, J., Frangioni, J. V., & Vahrmeijer, A. L. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117222
New and emerging therapies in heart failure
Rosano, G. M. C., Filippatos, G. S., & Starling, R. C. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0052
Self-citationKatoh, M., Ko, T., Katagiri, M., Yamada, S., Ito, M., & Komuro, I. (2023) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2022.37
Insuffisance cardiaque à fraction d’éjection réduite : révolution thérapeutique et défis persistants
Plane, A.-F. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2025.10.012
Microtubule-associated protein 4 forms aggregates consisting of helical filaments
Miura, S., Ishibashi, E., Nakamichi, T., Uwai, K., Kuragano, M., & Tokuraku, K. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102118
Selección de lo mejor del año 2021 en insuficiencia cardiaca
González‐Costello, J., Bagudá, J. D. J., Santiago‐Vacas, E., Dobarro, D., Manito‐Lorite, N., & Mayoral, A. R. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2021.11.001
Lösliche Guanylatzyklase(sGC)-Stimulation mit Vericiguat
Haase, N., Kedziora, S. M., Müller, D. N., & Dechend, R. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00576-y
Oh, H. E., & Hyun, J. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0076
Duignan, S. M., Pignatelli, R. H., & McMahon, C. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11851-7.00072-0
Gonçalves, A. V., Carvalheiro, R. M. M. M., Fiarresga, A. J., Pereira‐da‐Silva, T., & Cardim, N. M. (2026) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2026.03.014
Troponin: biology, molecular mechanisms, and multidimensional clinical applications
Adamcová, M., & Petráň, L. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00597-z
Gardner, R. S., McDonagh, T. A., & Clark, A. L. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780198766223.003.0069
Pharmacology in Noninvasive Ventilation in Cardiac Pulmonary Edema
Öcal, S., & Sağlam, C. E. (2023) · Noninvasive ventilation. The essentials · doi:10.1007/978-3-031-44626-9_39
Cardiovascular diagnostic methods in patients with diabetes mellitus. A review
Ramón-Ríos, A., Espejel-Guzman, A., Cabello‐Ganem, A., Serrano‐Roman, J., Aparicio-Ortiz, A. D., Fernández-Badillo, V., Palacios-Cruz, M., & Espinola-Zavaleta, N. G. (2023) · Gaceta Médica de México · doi:10.24875/gmm.22000383
Wirkt die moderne pharmakologische Herzinsuffizienztherapie antiarrhythmisch?
Boehmer, A. A., Rothe, M., & Ehrlich, J. R. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2666-3061
Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations
Trivedi, A., Hsu, C., Jafarinasabian, P., Terminello, B., Zhang, H., Flach, S. D., Israel, S., Brooks, A., Xue, H., Darpö, B., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14939
Self-citationA kardiális miozinaktivátorok klinikai alkalmazhatósága a preklinikai vizsgálatok tükrében
Ráduly, A. P., Sárkány, F., Kovács, M. B., Juhász, B., Horváth, B., Szentandrássy, N., Nánási, P. P., Edes, I. F., Csanádi, Z., Tóth, A., et al. (2023) · Cardiologia Hungarica · doi:10.26430/chungarica.2023.53.5.476
Relationship between Systolic Ejection Time and Inflammation in End-Stage Heart Failure
Gutovitz, J., Kutcher, J., Cherney, D. Z., Schiller, Y., Gabizon, I., Keshet, E., Rimon, J., Koren, D., Rao, V. A., & Grosman‐Rimon, L. (2025) · Southern Medical Journal · doi:10.14423/smj.0000000000001801
Takata, M., Nishikawa, M., Hayashi, H., Yamamura, A., Saku, K., Kawada, T., Sato, M., Kawahito, S., & Kinoshita, H. (2025) · Cureus · doi:10.7759/cureus.87854
Li, X., Li, H., Xu, H., Yuan, F., Chen, H., Liu, C., Yang, M., Li, J., & Sheng, L. (2025) · Drugs in R&D · doi:10.1007/s40268-025-00532-7
Self-citationInotropic agents in heart failure
Langanecha, B. D., Floh, A. A., Jean-st-michel, E. M., & Schwartz, S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13279-7.00022-5
Heart failure: pathophysiology and the emergence of novel therapies
Silva‐Cardoso, J., Moreira, E., Santos‐Ferreira, D., & Leite-Moreira, A. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00016-4
Recommendation: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R0/PR3
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr3
Recommendation: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R2/PR9
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr9
Recommendation: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R1/PR6
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr6
Review: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R0/PR2
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr2
Decision: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R1/PR7
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr7
Author comment: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R1/PR5
Halliday, B. P. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr5
Decision: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R2/PR10
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr10
Author comment: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R0/PR1
Halliday, B. P. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr1
Author comment: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R2/PR8
Halliday, B. P. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr8
Decision: Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift? — R0/PR4
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24.pr4
Evidence for a role of adverse sarcomere signaling in atrial fibrillation induction
McCauley, M. D., & Solaro, R. J. (2026) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2026.100866
D’Amario, D., Paglianiti, D. A., Laborante, R., Elia, S., Rizzo, G. E., Giubilato, S., Catalano, M. R., Amico, F., Volterrani, M., Restivo, A., et al. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag072
Evolutions in care, unmet needs, and research priorities in heart failure
Halliday, B. P., Ahmed, F. Z., Beezer, J., Fuat, A., Ludman, A. J., Pellicori, P., Savage, H. O., Taylor, C. J., & Cleland, J. G. F. (2024) · Considerations in Medicine · doi:10.1136/conmed-2024-000010
Self-citationBasile, P., Falagario, A., Carella, M. C., Dicorato, M. M., Monitillo, F., Santoro, D., Naccarati, M. L., Pontone, G., Ciccone, M. M., Santobuono, V. E., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061951
Genetic Dilated Cardiomyopathy: A Review
Boslough, M., Taylor, M. R. G., Mestroni, L., & Lombardi, R. (2026) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1849
Metadata
- Authors
- Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., Böhm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlström, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Macdonald, P., Mareev, V., Momomura, S.-I., O’Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., & Kurtz, C. E.
- Affiliations
- San Francisco VA Medical Center (US)
- From the Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco (J.R.T.), Amgen, Thousand Oaks (L.S., J.C.L., N.H., S.A.A., C.E.K.), and Cytokinetics, South San Francisco (F.I.M.) — all in California; Estudios Clínicos Latino América, Rosario, Argentina (R.D.); the Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute, Durham (G.M.F.), and the University of North...
- Brigham and Women's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- University of Minnesota (US)
- Linköping University (SE)
- University of Bern (CH)
- ORCID
- Teerlink, John R.
- Felker, G. Michael
- McMurray, John J.V.
- Metra, Marco
- Solomon, Scott D.
- Anand, Inder
- Böhm, Michael
- Bonderman, Diana
- Cleland, John G.F.
- Dahlström, Ulf
- Fang, James C.
- Filippatos, Gerasimos
- Fonseca, Cândida
- Goudev, Assen R.
- Howlett, Jonathan G.
- Lanfear, David E.
- Li, Jing
- Lund, Mayanna
- Macdonald, Peter
- Momomura, Shin-ichi
- O’Meara, Eileen
- Parkhomenko, Alexander
- Ponikowski, Piotr
- Sliwa, Karen
- Voors, Adriaan A.
- Zannad, Faiez
- Abbasi, Siddique A.
- Malik, Fady I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 105-116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3098430919
- Cited by
- 656
- References
- 26
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 76 · 2023: 150 · 2022: 130 · 2021: 148
- FWCI
- 68.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- RUC (Universidade Da Coruña) (submittedVersion)
- Funders
- Amgen
- Cytokinetics Inc.
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- omecamtiv mecarbil, cardiac myosin activator, heart failure with reduced ejection fraction, cardiovascular outcomes, heart failure hospitalization, cardiovascular mortality, N-terminal pro-brain natriuretic peptide, cardiac troponin I, symptom burden, pharmacokinetic-guided dosing, ventricular arrhythmias
- MeSH terms
- Aged, Aged, 80 and over, Cardiotonic Agents, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Myocardial Contraction, Stroke Volume, Urea, Cardiac Myosins, Heart Failure, Systolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.